Predict - a Translational Study to Predict Tumour Response to Neoadjuvant Treatment
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 800
- Locations
- 1
- Primary Endpoint
- Tumour response to treatment
Study Overview
Brief Summary
All adult patients with colorectal cancer presenting within the Sahlgrenska University Hospital or treated at any time at Sahlgrenska University Hospital are eligible and will be asked to participate. We already have biopsies taken at surgery in patients that receive surgery, but this study will include all patients and the biopsies will be taken during endoscopy for diagnosis of the primary tumour. Biopsies will then be taken during follow-up exams prior surgery but after neoadjuvant treatment. Biopsies will also be taken during surgery and in cases where surgery is not necessary biopsies will be taken regularly during follow-up exams.
Blood samples and in relevant cases urinary samples and mouth swabs will be taken at all timepoints when biopsies are taken. If it is not possible to take biopsies prior treatment blood samples will still be drawn.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Colorectal cancer
Exclusion Criteria
- •Not colorectal cancer
Outcomes
Primary Outcomes
Tumour response to treatment
Time Frame: 1-2 months after initiated treatment
Tumour microenviroment changes
Secondary Outcomes
- Normal tissue response to treatment(1month -3 years after treatment)
Investigators
Eva Angenete
PI
Sahlgrenska University Hospital, Sweden